Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2017 08:00 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day

VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
December 16, 2016 08:35 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics’ Subsidiary Launches JUXTAPID® (lomitapide) in Japan

VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first...
March 17, 2016 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

NEWARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced top line results from its pilot Phase 2 clinical study of MBX-8025 in patients with...
November 20, 2015 08:30 ET | Source: Aegerion Pharmaceuticals, Inc.

JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
June 16, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety

CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
September 24, 2014 09:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day

CAMBRIDGE, Mass., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
April 09, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
February 10, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
January 20, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
September 24, 2013 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day

CAMBRIDGE, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...

Next Page keyboard_arrow_right